Belinostat (a drug owned by Spectrum Pharmaceuticals Inc. and TopoTarget A/S).

TopoTarget posted friday that the BELIEF study have beaten the primary endpoint by the study:

Their Partner, Spectrum Pharmaceuticals didnt confirm those data, and there were some misunderstandings in the market. Today, spectrum announced the following comment about the BELIEF study.

For me, its clear, thare there are some misunderstandings in the partnerships between Spectrum and TopoTarget.

About Investor1989

Investor in stocks in about 5 years with some very good profits. Focusing on Biotech and Value stocks. Active investor...


Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.